Cargando…

Bendamustine: A review of pharmacology, clinical use and immunological effects

Bendamustine is an alkylating agent classified into the group of nitrogen mustard analogues, synthesized almost sixty years ago. It was registered in former East Germany in 1971 and approved by the US Food and Drug Administration in 2008 for treatment of chronic lymphocytic leukemia and indolent B-c...

Descripción completa

Detalles Bibliográficos
Autores principales: Lalic, Hrvoje, Aurer, Igor, Batinic, Drago, Visnjic, Dora, Smoljo, Tomislav, Babic, Antonija
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9100486/
https://www.ncbi.nlm.nih.gov/pubmed/35506458
http://dx.doi.org/10.3892/or.2022.8325
_version_ 1784706857395290112
author Lalic, Hrvoje
Aurer, Igor
Batinic, Drago
Visnjic, Dora
Smoljo, Tomislav
Babic, Antonija
author_facet Lalic, Hrvoje
Aurer, Igor
Batinic, Drago
Visnjic, Dora
Smoljo, Tomislav
Babic, Antonija
author_sort Lalic, Hrvoje
collection PubMed
description Bendamustine is an alkylating agent classified into the group of nitrogen mustard analogues, synthesized almost sixty years ago. It was registered in former East Germany in 1971 and approved by the US Food and Drug Administration in 2008 for treatment of chronic lymphocytic leukemia and indolent B-cell non-Hodgkin lymphoma. Considering its beneficial properties in the therapy of relapsed or refractory hematological malignancies, synergistic effects with other antineoplastic agents and increasing recent reports on its immunomodulatory effects, bendamustine has once again gained its justified attention. The uniqueness of bendamustine-mediated effects should be observed keeping in mind its distinctive structure with structural similarities to both alkylating agents and purine analogs. In the present review, the current knowledge on the use of bendamustine in oncology, its pharmacokinetics, mechanism of action and toxicity was summarized. In addition, its immune-modulating effects that have not been fully elucidated so far are emphasized, hoping to encourage further investigations of this unique drug.
format Online
Article
Text
id pubmed-9100486
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-91004862022-05-14 Bendamustine: A review of pharmacology, clinical use and immunological effects Lalic, Hrvoje Aurer, Igor Batinic, Drago Visnjic, Dora Smoljo, Tomislav Babic, Antonija Oncol Rep Review Bendamustine is an alkylating agent classified into the group of nitrogen mustard analogues, synthesized almost sixty years ago. It was registered in former East Germany in 1971 and approved by the US Food and Drug Administration in 2008 for treatment of chronic lymphocytic leukemia and indolent B-cell non-Hodgkin lymphoma. Considering its beneficial properties in the therapy of relapsed or refractory hematological malignancies, synergistic effects with other antineoplastic agents and increasing recent reports on its immunomodulatory effects, bendamustine has once again gained its justified attention. The uniqueness of bendamustine-mediated effects should be observed keeping in mind its distinctive structure with structural similarities to both alkylating agents and purine analogs. In the present review, the current knowledge on the use of bendamustine in oncology, its pharmacokinetics, mechanism of action and toxicity was summarized. In addition, its immune-modulating effects that have not been fully elucidated so far are emphasized, hoping to encourage further investigations of this unique drug. D.A. Spandidos 2022-06 2022-05-03 /pmc/articles/PMC9100486/ /pubmed/35506458 http://dx.doi.org/10.3892/or.2022.8325 Text en Copyright: © Lalic et al. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Review
Lalic, Hrvoje
Aurer, Igor
Batinic, Drago
Visnjic, Dora
Smoljo, Tomislav
Babic, Antonija
Bendamustine: A review of pharmacology, clinical use and immunological effects
title Bendamustine: A review of pharmacology, clinical use and immunological effects
title_full Bendamustine: A review of pharmacology, clinical use and immunological effects
title_fullStr Bendamustine: A review of pharmacology, clinical use and immunological effects
title_full_unstemmed Bendamustine: A review of pharmacology, clinical use and immunological effects
title_short Bendamustine: A review of pharmacology, clinical use and immunological effects
title_sort bendamustine: a review of pharmacology, clinical use and immunological effects
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9100486/
https://www.ncbi.nlm.nih.gov/pubmed/35506458
http://dx.doi.org/10.3892/or.2022.8325
work_keys_str_mv AT lalichrvoje bendamustineareviewofpharmacologyclinicaluseandimmunologicaleffects
AT aurerigor bendamustineareviewofpharmacologyclinicaluseandimmunologicaleffects
AT batinicdrago bendamustineareviewofpharmacologyclinicaluseandimmunologicaleffects
AT visnjicdora bendamustineareviewofpharmacologyclinicaluseandimmunologicaleffects
AT smoljotomislav bendamustineareviewofpharmacologyclinicaluseandimmunologicaleffects
AT babicantonija bendamustineareviewofpharmacologyclinicaluseandimmunologicaleffects